Rapid ART initiation on the day of diagnosis has been shown to increase the proportion of patients with virologic suppression at 10 months compared with initiation of therapy 2-4 weeks after diagnosis (64% vs 51%). However, rapid ART initiation with NNRTIs is not recommended owing to concerns about potential transmitted drug resistance. In addition, the NRTI abacavir should not be initiated until results of testing for the HLA-B*5701 allele are available.
According to HHS guidelines, genotypic testing is preferred over phenotypic testing to guide therapy in ARV-naive patients, as well as in patients in whom first- or second-line regimens produce a suboptimal virologic response or virologic failure.
Learn more about the management of drug-resistant HIV.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michael Stuart Bronze. Fast Five Quiz: Treatment-Resistant HIV - Medscape - May 10, 2021.